pharmacogenomics

Genetic Future

Category archives for pharmacogenomics

Mark Henderson has a great piece in the Times exploring the impact of personal genomics on the practice of medicine. The basic theme should be familiar to anyone who has been following the emergence of the personal genomics industry: doctors are currently almost completely unprepared for the onslaught of genetic information they are about to…

Warfarin (a.k.a. Coumadin, Jantoven, Marevan, or Waran) is the most widely-prescribed blood-thinning agent on the market. It’s also (in the words of Howard McLeod) a “terrible drug” – it has a very narrow therapeutic window, meaning that the minimal useful dose and the maximal safe dose are very close together. (The effects of over-dosing on…

In a comment on my previous post, Tera Eerkes is skeptical about the utility of routinely performing whole-genome sequencing on newborns: I found this comment absolutely fascinating, given the recent reports on translational analysis, that indicate an actual lack of clinical utility of KRAS testing and other drug-gene interactions. I believe these reports are indicative…